Literature DB >> 10027872

Optimization of magnesium therapy after severe diffuse axonal brain injury in rats.

D L Heath1, R Vink.   

Abstract

A number of studies have demonstrated that magnesium salts given after traumatic brain injury improve subsequent neurologic outcome. However, given that these earlier studies have used a number of different salts, dosages, and routes of administration, follow-up studies of the neuroprotective properties of magnesium are complicated, with comparisons to the earlier literature virtually impossible. The present study has therefore characterized the dose-response characteristics of the most commonly used sulfate and chloride salts of magnesium in a severe model of diffuse traumatic axonal injury in rats. Both magnesium salts improved neurologic outcome in rats when administered as a bolus at 30 min after injury. The i.v. and i.m. optima of each salt was 250 micromol/kg and 750 micromol/kg, respectively. The identical concentrations required for improved neurologic outcome suggest that improvement in outcome was dependent on the magnesium cation and not the associated anion. Subsequent magnetic resonance studies demonstrated that the administered magnesium penetrated the blood-brain barrier after injury and resulted in an increased brain intracellular free magnesium concentration and associated bioenergetic state as reflected in the cytosolic phosphorylation potential. Both of these metabolic parameters positively correlated with resultant neurologic outcome measured daily in the same animals immediately before the magnetic resonance determinations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027872

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

Review 1.  Vitamins and nutrients as primary treatments in experimental brain injury: Clinical implications for nutraceutical therapies.

Authors:  Cole Vonder Haar; Todd C Peterson; Kris M Martens; Michael R Hoane
Journal:  Brain Res       Date:  2015-12-23       Impact factor: 3.252

Review 2.  Magnesium neuroprotection is limited in humans with acute brain injury.

Authors:  J Andrew McKee; Randall P Brewer; Gary E Macy; Cecil O Borel; James D Reynolds; David S Warner
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 3.  Multifunctional drugs for head injury.

Authors:  Robert Vink; Alan J Nimmo
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 4.  Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?

Authors:  Niklas Marklund; Lars Hillered
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 5.  Pharmacological treatment of traumatic brain injury: a review of agents in development.

Authors:  J Hatton
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 6.  Use of magnesium in traumatic brain injury.

Authors:  Ananda P Sen; Anil Gulati
Journal:  Neurotherapeutics       Date:  2010-01       Impact factor: 7.620

7.  Dietary patterns in clinical subtypes of multiple sclerosis: an exploratory study.

Authors:  Geeta S M Ramsaransing; Sanne A Mellema; Jacques De Keyser
Journal:  Nutr J       Date:  2009-08-10       Impact factor: 3.271

8.  A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: an immunohistochemical and behavioral study.

Authors:  Erzsébet Kövesdi; Péter Bukovics; Valérie Besson; József Nyirádi; János Lückl; József Pál; Balázs Sümegi; Tamás Dóczi; István Hernádi; András Büki
Journal:  Int J Mol Sci       Date:  2010-03-26       Impact factor: 5.923

9.  Magnesium sulfate treatment in experimental spinal cord injury: emphasis on vascular changes and early clinical results.

Authors:  Erkan Kaptanoglu; Etem Beskonakli; Ihsan Solaroglu; Asuman Kilinc; Yamac Taskin
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

10.  Stress and traumatic brain injury: a behavioral, proteomics, and histological study.

Authors:  Sook-Kyung C Kwon; Erzsebet Kovesdi; Andrea B Gyorgy; Daniel Wingo; Alaa Kamnaksh; John Walker; Joseph B Long; Denes V Agoston
Journal:  Front Neurol       Date:  2011-03-07       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.